Saudi Arabia vs United Arab Emirates: Share of E. coli infections resistant to cephalosporins
Saudi Arabia
52.8%
in 2022
United Arab Emirates
52.4%
in 2022
Saudi Arabia rank
15th
United Arab Emirates rank
17th
Share of E. coli infections resistant to cephalosporins over time
- Saudi Arabia
- United Arab Emirates
How they compare
Saudi Arabia currently reports 52.8% against 52.4% in United Arab Emirates, a difference of 0.4%.
Across all 6 years both countries report, Saudi Arabia has been ahead every year.
Saudi Arabia ranks 15th and United Arab Emirates ranks 17th of 46 countries.
Saudi Arabia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Saudi Arabia | United Arab Emirates | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 54.3% | 47.5% | 6.8% | Saudi Arabia |
| 2020s | 54.7% | 52.7% | 2.0% | Saudi Arabia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of e. coli infections resistant to cephalosporins, Saudi Arabia or United Arab Emirates?
- Saudi Arabia, at 52.8% against 52.4% in United Arab Emirates as of 2022.
- What is the difference in share of e. coli infections resistant to cephalosporins between Saudi Arabia and United Arab Emirates?
- 0.4%, with Saudi Arabia ahead.
- How many years of comparable data are there for Saudi Arabia and United Arab Emirates?
- 6 years are reported by both, from 2017 to 2022.
- How do Saudi Arabia and United Arab Emirates rank globally for share of e. coli infections resistant to cephalosporins?
- Saudi Arabia ranks 15th and United Arab Emirates ranks 17th of 46 countries.
- Where does this data come from?
- World Health Organization – processed by Our World in Data, published as Share of E. coli infections resistant to cephalosporins. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%).